Notch is out — your watchlist beside the MacBook notch, synced with this account.
Learn more ↗We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Auto-summary of recent filing activity and financial trends · not investment advice
Samsung Biologics had a high proportion of routine disclosures, including miscellaneous filings and disclosure amendments (5 cases), and its periodic reports were duly submitted. On the financial front, revenue rebounded to around KRW 1.3 trillion in Q2 2026 after plunging in Q4 2025; however, net profit has recorded a gradual quarterly decline, warranting continued monitoring of its profitability trends.
Latest filings collected from DART (electronic disclosure system)
